 In this video, I'm going to talk about a penny stock that BlackRock and Vanguard buy and hold. This is a very interesting one. We'll go through it in this video. I've got to say, I'm not a financial advisor. I'm a business teacher in my day life, but I'm by no means an expert on the stock market. And I've been doing some research for you today and I'm looking at stocks where institutions seem to be buying heavily or holding heavily, right? Because I do think that adds credibility to the stock with it being a penny stock if big institutions are buying the stock. So let's go into the information here in this video. So first of all, we're going to establish a penny stock play and then we're going to understand the strategy for this penny stock as well. So stay right to the end of the video so you get the full strategy and we play this in a smart way in these market volatile times. And I've got to say, overall, as the correction happens, it just creates buying opportunities. It creates bargain prices. So that's the way that you've got to see it and this is no different. Let's look into it. Okay. First of all, Vanguard Group, they earn 2.26 million shares. Then you've got BlackRock over 2 million shares as well of this particular penny stock. And this one is being heavily bought by institutions. Now, there is more buying of this stock by institutions than there is selling at the moment. And there's a good reason for this and I'll go through the research for you in a moment. Before that, if you could do as a favor and smash that like button because it really does help out the channel, help grow this channel to 15,000 subscribers. So if you do appreciate me bringing this research and these videos to you, then do subscribe and like the video and hit that notification bell so that you never miss a new video when we talk about the latest penny stocks or general stocks to buy as well because you've got to have those long-term ones. Thanks for all the support. Let's go into it. So what we're gonna talk about here is the ticker symbol is C-E, C-E-R-C. Okay. So this is Cericor, okay. And you can see here that it has had a bit of a beat down from its previous highs all the way down here. Now, we could see it come down to sort of this lower $3 level, you know, $3, $3.10. So I think there's still a chance for it to go down a bit further. But I do think that it's got a lot of potential and we're gonna go through why. So what are they? So they are unparalleled in rare pediatric and orphan disease pipeline. So they've got a building, a global biopharmaceutical enterprise with a near-term pipeline of six clinical, six. Not one, not two, six clinical programs. All of our pipeline products have unique and novel mechanisms of action with the potential to be first class in punk compounds. Our focus is the development of innovative therapies in areas of unmet needs, okay. So looking in this, they've got a lot of stuff in their pipeline. If you take a look at this image here, you can see all the different areas that they've got in their pipeline. So these are in preclinical phase one and phase two. And of course they've then got to get up to phase three and then FDA approved. But at the end of the day, they've got a lot of products there. Some of these biopharmaceutical companies, some of them only have maybe one or two products in their pipeline. And of course that is a bit more high risk because what if they don't get approved or what if they both don't get approved? The stock would tank. Now, this company has got a range of products in their pipeline, which means that even if just a few of them succeed, then it's still got a lot of potential. So I would say in comparison, this is still a risky stock because it's a penny stock. So you got to bear that in mind, high risk, high reward. But I feel that it's less risky than some other biopharmaceutical stocks because they've got a range of products in their pipeline. So if one or two don't get through, at least maybe some of this will anyways. So I like that. I kind of like that. It kind of adds a little kind of safety cushion to the stock itself. Okay, so it's got a range of pipeline in its products. Now, some recent news, what is the recent news? So, Sereco announced fast track designation for SIRC 803 for the treatment of this particular area here. So they've actually announced some fast track. They've announced the fast track in terms of this particular product and in terms of the FDA. So they've granted fast track designation to this here. So which is good to see that, you know, this is now being granted a fast track approach. So that sends good positive signs about this potential stock. Okay, now we also got this executive summary here from their investor relations presentation. Now they've got this successful proof of concept for the virus as well. So they've got some products that can help with that. In that sense, so they've got single dose and it's demonstrated robust improvement in the primary endpoint. So they've got a product for this particular situation here and it plans to meet with the FDA regarding a registration type trial and filing for breakthrough. So that's a catalyst. There's a lot of catalysts that can happen in this particular stock because of the amount of different products that they're producing. They've got a range of products in the pipeline and they're all catalysts in their own right. So there's a lot of stuff going on. Now also it's announced an additional shares of common stock, right? Okay, and that was in January but it's kind of just good to notice that they are raising cash. I don't have a problem with them raising cash and offering a public offering. I don't see it, I don't see a problem with that. I think it's important for some companies to actually do that. I think it's a bit annoying when they do it too often but I think that if they're raising capital, if they're raising cash, that's only a good thing to me. So they've raised 40.7 million and this was at a price of $2.60 per share. So not far off its current price at the moment, okay? Of $3.55. Now, how are we gonna play this one? Now the first thing to mention is a biopharmaceutical player is incredibly risky because it can go up, it can go down massively based upon the results of the products that they're creating. In relation to that, at least they've got a range of products that they're creating and actually that can be a bit of a cushion. So if some don't get through, another's do, then it's a bit more of a safer biopharmaceutical player, albeit still very risky with it being a penny stock. Now, it seems to be a good company, seems to be interesting what they're doing there. They've got a range of products, I'm liking what I'm seeing and then also they've been raising capital, 40.7 million, you know, BlackRock, BlackRock and Vanguard keep buying this stock so they must have some intel which tells me that they like this stock, they're buying and holding, okay. So looking into this, you can see the price, 355. So how do we play the strategy on this? What is the strategy? Well, what I would do is I'm putting it on the watch list and if I see it get down to, with these market volatile times at the minute, if it can sort of get down to that $3 level, I think that that potentially is a buying opportunity. I think you could potentially look at buying now again, I'm not a financial advisor and kind of maybe this is the floor for it in terms of where it's gonna go and then maybe after this it's gonna run up but I think that it could go down a bit further from its current price and if you can get it towards that $3 or high $2 range, I think that this one is definitely gonna go to sort of $5, $6, $7 in towards the future, I really do believe that. So I think it's got a lot of potential in this stock. I do just think it is one of these to put on the radar, watch it patiently and get in at a price that you feel comfortable with really. So that's what the strategy that I would say for this is look to see if you can get it at low $3 or the high $2 range, okay? And then ride this one up for a potential double up if you can, okay? Now, that's what I've got for this video. Hopefully you enjoyed that. Smash the like button, turn on the notification bell if you just don't ever miss a new video and subscribe to the channel. Let's try to get to 15,000 subscribers and I wanna thank everybody for all the support on the channel. I really do appreciate it and I'll see everybody in the next one.